Skip to main content

Table 1 Studies reporting the prevalence of nontuberculous mycobacteria in cystic fibrosis populations

From: Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis

Study Study year Location Design Included CF patients NTM cases NTM revalence % MABSC % MAC
Boxerbaum B. 1980 OH, USA Prospective 430 8 1.8 75* 0
Smith MJ et al. [21] 1984 UK Prospective 223 4 1.8 25* 0
Hjelte L et al. [22] 1990 Sweden Prospective 54 5 9.2 0 60
Kilby JM et al. [23] 1992 NC, USA Prospective 87 17 19.5 29* 76
Aitken ML et al. [24] 1993 WA, USA Prospective 64 8 12.5 0 88
Hjelt K et al. [25] 1994 Denmark Prospective 185 7 3.8 71* 29
Sermet-Gaudelus I et al. [26] 1996-99 France Prospective 296 29 9.8 52 21
Fauroux B et al. [27] 1997 France Prospective 106 7 6.6 43* 0
Mussaffi H et al. [28] 1997-02 Israel Retrospective 139 12 8.6 67§ 25§
Esther CR Jr et al. [29] 2000-07 NC, USA Registry 1,216 166 13.7 41 59
Pierre-Audigier C et al. [30] 2000 France Prospective 385 31 8.1 42 23
Oliver A et al. [19] 2000 Spain Prospective 37 6 16.2 50* 33
Radhakrishnan et al. [31] 2004 Canada Prospective 98 6 6.1 33 67
Levy I et al. [32] 2001-03 Israel Cross-sectional 186 42 22.6 31 14
Olivier KN et al. [33] 2002 USA Prospective 986 128 13.0 20 72
Roux AL et al. [34] 2004 France Prospective 1,582 104 6.6 48 22
Valenza et al. [35] 2006 Germany Prospective 60 8 13.3 50 50
Chalermskulrat W et al. [36] 2006 OH, USA Retrospective 132 26 19.7 46 50
Binder AM et al. [37] 2011 USA Registry 5,403 191 3.5 36 64
  1. * = M. chelonae reported, but is here included as MABSC due to historical changes in taxonomy. § = percentage based on 6 chronic NTM cases.